U.S. Court in Massachusetts Allows Kickback Claim, But Requires Demanding Causation Standard for False Claims Allegations
- September 29, 2023
The U.S. District Court for the District of Massachusetts refused to grant Regeneron Pharmaceuticals, Inc. summary judgment on the federal government’s claim that the company violated the Anti-Kickback Statute (AKS) by improperly funneling millions of dollars to a Chronic Disease Fund (CDF) to subsidize patient copays for its drug Eylea, which is used to treat age-related macular degeneration.
ARTICLE TAGS
You must be logged in to access this content.